We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Cystic Fibrosis Test Aids in Parent and Newborn Screening

By LabMedica International staff writers
Posted on 17 Sep 2009
A new cystic fibrosis (CF) test screens potential parents to determine if they are carriers of CF-causing gene mutations and in confirmatory diagnostic testing in newborns and children.

The xTAG Cystic Fibrosis 39 kit (v2) detects 39 CF-causing gene mutations, including the 23 CF transmembrane conductance regulator (CFTR) gene mutations and four variants (polymorphisms) recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG), as well as 16 additional CFTR gene mutations from human blood specimens. More...
The xTAG kit is flexible, offering physicians the ability to select the CFTR gene mutations for which they want to test, up to the entire panel of 39 CFTR gene mutations.

This flexibility is intended to allow laboratories to avoid having to use different platforms for various testing purposes, thus saving time and resources. Additionally--similar to the first-generation xTAG CF test (v1)--the new xTAG Cystic Fibrosis 39 kit v2 does not require reflex testing; all results are revealed and available for analysis at each run, if necessary. The protocol for testing has been streamlined to make the process faster and easy to use. The xTAG Cystic Fibrosis 39 kit (v2) is a product of Luminex (Austin, TX, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"The first FDA-cleared molecular diagnostic test for cystic fibrosis demonstrated Luminex's leadership in innovative CF testing. With this improved product, we focused on our customers' need to have a faster and easier to use IVD-cleared test with broad genetic mutation coverage,” said Patrick J. Balthrop, President and CEO of Luminex. "The xTAG Cystic Fibrosis 39 kit v2 gives doctors the ability to quickly, accurately and effectively screen potential parents for CF gene mutations and diagnose the disease early, which will assist in improving the health and quality of life of people with CF around the world.”

CF is a chronic inherited genetic disease in which the body produces thick, sticky mucus that can clog the lungs and affect the digestive system, and can have debilitating and potentially life-threatening consequences. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, of which over 1,500 have been identified to date. Late diagnosis of the disease is associated with chronic lung infections and compromised growth, whereas early detection and treatment has been shown to reduce therapeutic needs, lower rates of complications, and increase life expectancy.

Related Links:

Luminex




New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.